Table 1 Baseline demographic and clinical characteristics of the ADNI cohort for A β-positive subjects and all subjects
From: Predicting progression and cognitive decline in amyloid-positive patients with Alzheimer’s disease
Overall Aβ-positive | Missing | CN | MCI | AD | All subjects | All missing | ||
|---|---|---|---|---|---|---|---|---|
n | 749 | 132 | 411 | 206 | 2293 | |||
AGE, mean (SD) | 73.7 (7.2) | 1 | 75.2 (6.0) | 73.2 (7.0) | 73.6 (8.1) | 73.2 (7.2) | 9 | |
Gender, n (%) | m | 415 (55.4) | 0 | 55 (41.7) | 247 (60.1) | 113 (54.9) | 1217 (53.2) | 5 |
f | 334 (44.6) | 77 (58.3) | 164 (39.9) | 93 (45.1) | 1071 (46.8) | |||
MMSE, mean (SD) | 26.5 (2.8) | 0 | 29.0 (1.2) | 27.4 (1.9) | 23.3 (2.0) | 27.4 (2.66) | 5 | |
ADAS13, mean (SD) | 20.1 (9.6) | 5 | 10.2 (4.6) | 18.4 (6.7) | 30.3 (7.7) | 17.0 (9.25) | 29 | |
TAU, mean (SD) | 337.1 (139.2) | 7 | 281.5 (102.5) | 334.3 (141.9) | 378.6 (141.5) | 285.6 (132.9) | 1010 | |
ABETA42, mean (SD) | 754.0 (320.0) | 0 | 885.3 (396.5) | 761.5 (311.6) | 654.8 (240.7) | 1090.7 (607.5) | 1014 | |
FDG, mean (SD) | 1.19 (0.15) | 157 | 1.29 (0.11) | 1.22 (0.14) | 1.06 (0.13) | 1.23 (0.15) | 806 | |
APOE4, n (%) | 0 | 245 (34.5) | 39 | 63 (50.4) | 133 (34.5) | 49 (24.6) | 1162 (54.1) | 147 |
1 | 345 (48.6) | 56 (44.8) | 187 (48.4) | 102 (51.3) | 780 (36.4) | |||
2 | 120 (16.9) | 6 (4.8) | 66 (17.1) | 48 (24.1) | 204 (9.5) | |||
Hippocampus, mean (SD) | 6517.6 (1091.6) | 168 | 7300.8 (788.8) | 6585.0 (1029.8) | 5883.8 (1008.4) | 6794.0 (1185.7) | 806 | |
AV45, mean (SD) | 1.37 (0.20) | 312 | 1.29 (0.21) | 1.36 (0.20) | 1.44 (0.18) | 1.21 (0.23) | 1205 | |
ABETARatio, mean (SD) | 0.087 (0.029) | 0 | 0.094 (0.020) | 0.086 (0.023) | 0.084 (0.023) | 0.129 (0.057) | 1014 |